Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies
NCT05455294Phase 1Active, not recruiting
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navitoclax in Myeloid malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 2 more (5 arms). Primary endpoints: Recommended Phase 2 Dose at 28 days and Dose Limiting Toxicity at 28 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
Myeloid malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05455294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455294.